Latest Interleukin 2 Stories
NKTR-214 Demonstrates Improved Efficacy in Resistant Preclinical Melanoma Model Through Preferential Activation of Tumor Killing Immune Cell Subtype SAN FRANCISCO, April 7, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research (AACR) Annual Meeting. NKTR-214 is a new immunocytokine that is being developed...
WALTHAM, Mass., Dec. 22, 2011 /PRNewswire/ -- Provenance Biopharmaceuticals Corp. ("Provenance") announced today the closing of an $8 million financing arrangement with Alopexx Enterprises, LLC for the continued development of anti-cancer therapeutic, DI-Leu16-IL2. DI-Leu16-IL2 is among a class of molecules called immunocytokines that are being developed for the treatment of various forms of cancer. Immunocytokines, combine the immune stimulating features of cytokines with the...
Research describes advantages of new vaccine adjuvant New research from the laboratory of Dr. Elizabeth Leadbetter at the Trudeau Institute may lead to a whole new class of vaccines. Dr. Leadbetter's lab has discovered new properties of a potential vaccine adjuvant that suggest it could be useful for enhancing protection against a number of different infections. This new data will be published in the January 2012 issue of the journal Nature Immunology (Vol. 13, pp. 44-50). The paper, "iNKT...
SAN DIEGO, Oct. 11 /PRNewswire/ -- More than 120 cancer survivors and caregivers, cancer-treating physicians, and patient advocates gathered in San Diego to share their Proleukin® (aldesleukin for injection) treatment experiences. The theme of the meeting, Celebrating Our (Un)Common Journey Patient Summit, is believed to be the largest-ever gathering of metastatic renal cell carcinoma (kidney cancer) and metastatic melanoma (skin cancer) survivors. The Summit, which featured a series...
In an acute viral infection, most of the white blood cells known as T cells differentiate into cells that fight the virus and die off in the process. But a few of these "effector" T cells survive and become memory T cells, ensuring that the immune system can respond faster and stronger the next time around.Scientists have identified a molecule that defines which cells are destined to become memory T cells just a few days after a viral infection begins. The finding could guide the...
SAN DIEGO, Jan. 26 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a commercialization agreement with Novartis under which Prometheus acquired exclusive rights to distribute, promote and sell PROLEUKIN® (aldesleukin) in the United States. Proleukin is a recombinant human interleukin-2 for treatment in adults with metastatic melanoma and metastatic kidney cancer. Net sales for Proleukin were approximately...
Australian scientists have made a discovery that may one day remove the need for a lifetime of toxic immunosuppressive drugs after organ transplants. Professor Jonathan Sprent and Dr Kylie Webster from Sydney's Garvan Institute of Medical Research, in collaboration with colleagues, Dr Shane Grey and Stacey Walters, have successfully tested a method, in experimental mice, of adjusting the immune system for just long enough to receive a tissue transplant and accept it as 'self'. At no...
